Actively Recruiting

Phase 4
Age: 18Years - 60Years
All Genders
NCT06775197

Partial Meniscal Replacement with Spongioflex®

Led by Maria-Josef-Hospital Greven · Updated on 2025-01-15

40

Participants Needed

1

Research Sites

365 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this investigator-initiated trial is to evaluate whether the novel graft can prevent/reduce the disadvantages of the previously used replacement materials and shows better results than the group of patients, which were not operated. Since there is currently no alternative made of biological material to this product, this investigator-initiated trial is of great medical and economic importance. The otherwise following arthrosis or knee prosthesis implantation (TKA ) could be prevented or at least postponed. Initial clinical results are promising. An important and sensitive parameter for assessing the postoperative function of the meniscus is the MRI image. Genovese et al. 2007 were able to show in a categorization/classification which magnetic resonance image can be expected in the case of successful incorporation. Several studies have shown that the known clinical knee scores (Lysholm, IKDC, KOOS, VAS pain) improve significantly after successful ingrowth of the meniscus implant.

CONDITIONS

Official Title

Partial Meniscal Replacement with Spongioflex®

Who Can Participate

Age: 18Years - 60Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged 18 to 60 years
  • Partial loss of lateral meniscus with lateral joint line pain or medial meniscus with medial joint line pain
  • Sufficient standing of the peripheral rim to allow the procedure
  • Signed written informed consent to participate and provide scientific data in pseudonymized form
Not Eligible

You will not qualify if you...

  • Unresolved anterior cruciate ligament insufficiency within 16 weeks after implantation
  • Knee axial deviation greater than 2� varus or valgus
  • Realignment osteotomy not performed within 12 weeks
  • Advanced cartilage damage (grade III ICRS) or osteoarthrosis (grade III Kellgren and Lawrence) in affected compartment
  • Extension deficit over 3� compared to opposite side or knee flexion less than 125�
  • Inflammatory arthritis or synovitis of the treated knee
  • Body Mass Index over 30 kg/m�
  • Chronic pain patients
  • Age under 18 or over 60 years
  • Increased anesthesiologic risk, bleeding risk, or infection risk for operated patients
  • Necrotic, infected, or poorly perfused host tissue
  • History of allergic reactions
  • Acute hypersensitivity to the implant or its excipients
  • Pregnant women

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Maria-Josef-Hospital Greven GmbH

Greven, North Rhine-Westphalia, Germany, 48268

Actively Recruiting

Loading map...

Research Team

C

Clemens Kösters, PD, Dr. med.

CONTACT

D

Daniel A den Toom, Dr. med

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here